ALYFTREK

Serial Number 98760764
Registration 7805273
700

Registration Progress

Application Filed
Sep 20, 2024
Under Examination
Feb 4, 2025
Approved for Publication
Dec 10, 2024
Published for Opposition
Dec 10, 2024
Registered
May 20, 2025

Trademark Image

ALYFTREK

Basic Information

Serial Number
98760764
Registration Number
7805273
Filing Date
September 20, 2024
Registration Date
May 20, 2025
Published for Opposition
December 10, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
May 20, 2025
Registration
Registered
Classes
005

Rights Holder

Vertex Pharmaceuticals Incorporated

03
Address
50 Northern Avenue
Boston, MA 02210

Ownership History

Vertex Pharmaceuticals Incorporated

Original Applicant
03
Boston, MA

Vertex Pharmaceuticals Incorporated

Owner at Publication
03
Boston, MA

Vertex Pharmaceuticals Incorporated

Original Registrant
03
Boston, MA

Legal Representation

Attorney
Sarah Anne Keefe

USPTO Deadlines

Next Deadline
2130 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-05-20)
Due Date
May 20, 2031
Grace Period Ends
November 20, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

24 events
Date Code Type Description Documents
May 20, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
May 20, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 25, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Apr 25, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Apr 23, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Apr 22, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Feb 10, 2025 IUAF S USE AMENDMENT FILED Loading...
Feb 10, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Feb 4, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 10, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 10, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 4, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 13, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 13, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 13, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Nov 13, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Nov 13, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Nov 7, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 7, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 7, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 7, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Oct 14, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 14, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Sep 20, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of cystic fibrosis
First Use Anywhere: Jan 8, 2025
First Use in Commerce: Jan 8, 2025

Additional Information

Design Mark
The mark consists of the stylized word "ALYFTREK" in teal beneath a design consisting of a purple curved shape which is broad at one end and tapered on the other end, shown with twelve orange circles of differing sizes.
Color Claim
The colors orange, purple, and teal are claimed as features of the mark.

Classification

International Classes
005